ZTS Stock Analysis: Zoetis | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 31.677m USD | 12M Return: -50.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 487M
EPS Trend: 99.4%
Qual. Beats: -1
Rev. Trend: 96.0%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zoetis Inc. (NYSE: ZTS) is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions. It was incorporated in 2012 in connection with its spin-off from Pfizer, and it IPOd on the NYSE in February 2013. The company is classified within the Health Care sector (Pharmaceuticals sub-industry) under GICS, and operates as a large-cap U.S. issuer.
The business is organized around two end markets: companion animals (dogs, cats, and horses) and livestock (cattle, swine, poultry, fish, and sheep). Core product categories include parasiticides, vaccines, dermatology, anti-infectives, pain and sedation products, and other pharmaceuticals. Zoetis sells primarily to veterinarians, livestock producers, and pet owners, with companion animal products generally serving as the higher-margin segment of the animal health industry due to more inelastic demand and insurance-driven spending.
Beyond drugs and vaccines, Zoetis offers point-of-care diagnostics, lab instruments and reagents, rapid immunoassay tests, reference laboratory services, blood glucose monitors, and non-pharmaceutical lines such as nutritionals, biodevices, and genetic testing. The company has a collaboration with Blacksmith Medicines to develop novel antibiotics for animal use, reinforcing its R&D pipeline focus. Zoetis is headquartered in Parsippany, New Jersey.
- Companion animal revenue and margins outpace livestock segment
- New dermatology and pain products like Librela accelerate growth
- Livestock demand tied to global protein consumption trends
| Net Income: 2.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -2.08 > 1.0 |
| NWC/Revenue: 46.49% < 20% (prev 26.84%; Δ 19.66% < -1%) |
| CFO/TA 0.18 > 3% & CFO 2.72b > Net Income 2.64b |
| Net Debt (7.49b) to EBITDA (4.03b): 1.86 < 3 |
| Current Ratio: 3.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (422.4m) vs 12m ago -5.71% < -2% |
| Gross Margin: 70.75% > 18% (prev 69.48%; Δ 1.27% > 0.5%) |
| Asset Turnover: 65.01% > 50% (prev 65.87%; Δ -0.85% > 0%) |
| Interest Coverage Ratio: 14.70 > 6 (EBIT TTM 3.54b / Interest Expense TTM 241.0m) |
| A: 0.29 (Total Current Assets 6.47b - Total Current Liabilities 2.05b) / Total Assets 15.2b |
| B: 0.94 (Retained Earnings 14.2b / Total Assets 15.2b) |
| C: 0.24 (EBIT TTM 3.54b / Avg Total Assets 14.6b) |
| D: 0.27 (Book Value of Equity 3.23b / Total Liabilities 11.9b) |
| Altman-Z'' = 6.88 = AAA |
| DSRI: 1.08 (Receivables 1.51b/1.36b, Revenue 9.51b/9.29b) |
| GMI: 0.98 (GM 69.48% / 70.75%) |
| AQI: 0.95 (AQ_t 0.31 / AQ_t-1 0.32) |
| SGI: 1.02 (Revenue 9.51b / 9.29b) |
| TATA: -0.00 (NI 2.64b - CFO 2.72b) / TA 15.2b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 16, 2026, the stock is trading at USD 74.53 with a total of 5,306,865 shares traded. Over the past week, the price has changed by -0.76%, over one month by -6.78%, over three months by -38.01% and over the past year by -50.49%.
Current recommended Stop Loss: 71.30 (which is 4.3% or 1.3 ATR below the current price).
Zoetis has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ZTS.
- StrongBuy: 9
- Buy: 3
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 115.7 | 55.2% |
P/E Trailing = 12.3062
P/E Forward = 10.9769
P/S = 3.3024
P/B = 9.7383
P/EG = 1.7999
Revenue TTM = 9.51b USD
EBIT TTM = 3.54b USD
EBITDA TTM = 4.03b USD
Long Term Debt = 9.04b USD (from longTermDebt, last quarter)
Short Term Debt = 53.0m USD (from shortTermDebt, last fiscal year)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 193.0m
Net Debt = 7.49b USD (calculated: Debt 9.43b - CCE 1.94b)
Enterprise Value = 39.2b USD (31.7b + Debt 9.43b - CCE 1.94b)
Interest Coverage Ratio = 14.70 (Ebit TTM 3.54b / Interest Expense TTM 241.0m)
EV/FCF = 18.34x (Enterprise Value 39.2b / FCF TTM 2.14b)
FCF Yield = 5.45% (FCF TTM 2.14b / Enterprise Value 39.2b)
FCF Margin = 22.46% (FCF TTM 2.14b / Revenue TTM 9.51b)
Net Margin = 27.79% (Net Income TTM 2.64b / Revenue TTM 9.51b)
Gross Margin = 70.75% ((Revenue TTM 9.51b - Cost of Revenue TTM 2.78b) / Revenue TTM)
Gross Margin QoQ = 71.66% (prev 68.87%)
Tobins Q-Ratio = 2.58 (Enterprise Value 39.2b / Total Assets 15.2b)
Interest Expense / Debt = 2.56% (Interest Expense 241.0m / Debt 9.43b)
Taxrate = 20.10% (665.0m / 3.31b)
NOPAT = 2.83b (EBIT 3.54b * (1 - 20.10%))
Current Ratio = 3.15 (Total Current Assets 6.47b / Total Current Liabilities 2.05b)
Debt / Equity = 2.92 (Debt 9.43b / totalStockholderEquity, last quarter 3.23b)
Debt / EBITDA = 1.86 (Net Debt 7.49b / EBITDA 4.03b)
Debt / FCF = 3.51 (Net Debt 7.49b / FCF TTM 2.14b)
Total Stockholder Equity = 4.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.07% (Net Income 2.64b / Total Assets 15.2b)
RoE = 62.41% (Net Income TTM 2.64b / Total Stockholder Equity 4.23b)
RoCE = 26.68% (EBIT 3.54b / Capital Employed (Equity 4.23b + L.T.Debt 9.04b))
RoIC = 22.33% (NOPAT 2.83b / Invested Capital 12.7b)
WACC = 5.30% (E(31.7b)/V(41.1b) * Re(6.27%) + D(9.43b)/V(41.1b) * Rd(2.56%) * (1-Tc(0.20)))
Discount Rate = 6.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.94 | Cagr: -3.94%
[DCF] Terminal Value 74.53% ; FCFF base≈2.19b ; Y1≈2.09b ; Y5≈1.98b
[DCF] Fair Price = 56.49 (EV 31.2b - Net Debt 7.49b = Equity 23.7b / Shares 419.2m; r=8.35% [WACC [floored]]; 5y FCF grow -6.36% → 2.50% )
EPS Correlation: 99.37 | EPS CAGR: 9.86% | SUE: -2.43 | # QB: -1
Revenue Correlation: 96.00 | Revenue CAGR: 5.56% | SUE: -1.16 | # QB: -1
EPS current Quarter (2026-06-30): EPS=1.86 | Chg30d=-0.01% | Revisions=-50% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.85 | Chg30d=-0.13% | Revisions=+15% | Analysts=13
EPS current Year (2026-12-31): EPS=6.87 | Chg30d=-0.39% | Revisions=-81% | GrowthEPS=+7.2% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=7.40 | Chg30d=-0.38% | Revisions=-81% | GrowthEPS=+7.7% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -62% (up=8, down=39)